Meiogen is awarded US Patents #7,285,526 and #7,887,814 B2
These patents cover the composition of the lead compound Normferon™, its modifications and its use in the treatment of a diverse range of immunological and neurological diseases.
Normferon™ is expected to be the first,
safest, and most effective interferon
Making interferon levels normal again
There are currently no FDA-approved interferon inhibitors available. Meiogen could be the first.
Meiogen Biotechnology Corporation © 2014